---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-023065"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:38:24.871919+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Delcath Systems Q1 2024 revenue jumps to $3.1M; raises center activation target to 20 by year-end

## Summary
- Revenue $3.1M, up from $0.6M YoY, driven by HEPZATO KIT sales of $2.0M and CHEMOSAT of $1.1M.
- Raised $7.0M in private placement; cash and investments total $27.2M at quarter end.
- Appointed Dr. Martha S. Rook as COO; expanded center activation goal to 20 by end of 2024.
- Received permanent J-code (J9248) and pass-through payment for HEPZATO KIT from CMS effective April 1.
- SG&A rose to $8.8M from $4.2M due to commercial launch; R&D decreased to $3.7M.

## SEC filing metadata
- accession: 0001628280-24-023065
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000162828024023065/0001628280-24-023065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000162828024023065/dcth-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-023065
- JSON: https://secwatch.observer/filing/0001628280-24-023065.json
- Plain text: https://secwatch.observer/filing/0001628280-24-023065.txt

## Key facts
- Earnings Releases
  DELCATH SYSTEMS, INC. reported the first quarter ended March 31, 2024 results: revenue $3.1 million.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $3.1 million
  - Result: reported results
  source text: Total revenue for the quarter ended March 31, 2024 was $3.1 million compared to $0.6 million for the same period in the prior year from our sales of HEPZATO in the U.S. and CHEMOSAT in Europe.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872912/000162828024023065/0001628280-24-023065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.